Chronic kidney disease (CKD) is one of the most common diagnoses in senior cats. Studies estimate that approximately 30–40% of cats over the age of 10 have some degree of CKD, and that figure rises with age. It is also one of the leading causes of death in the species. But CKD is not a single event — it is a progressive disease with a wide clinical spectrum, and the difference between a cat diagnosed at IRIS Stage 2 who lives another two to three years on a well-managed protocol and one who declines rapidly often comes down to how early the disease is staged and how systematically each complicating factor is addressed.

The International Renal Interest Society (IRIS) provides the staging framework that drives treatment decisions. This article walks through that framework, the substaging variables that matter independently of creatinine and SDMA, and the evidence behind each major treatment intervention — renal diet, phosphorus control, proteinuria management, and hypertension treatment — organized by stage.

IRIS staging: the framework that drives treatment

IRIS staging is based on fasting serum creatinine and SDMA, assessed when the cat is well-hydrated and clinically stable. A cat dehydrated from vomiting or anorexia will have an artificially elevated creatinine that does not reflect true kidney function. Acute kidney injury, urinary obstruction, and post-renal causes must be ruled out before staging.

IRIS Stage	Creatinine (mg/dL)	SDMA (μg/dL)	Typical clinical picture
1	< 1.6	< 18 (other evidence of CKD present)	No clinical signs. Diagnosed by imaging, urine concentrating defect, or persistently elevated SDMA > 14.
2	1.6–2.8	18–25	Mild clinical signs possible — subtle weight loss, polydipsia/polyuria. Many cats appear normal at home.
3	2.9–5.0	26–38	Moderate signs — reduced appetite, intermittent vomiting, muscle loss, poor coat quality.
4	> 5.0	> 38	Severe signs — marked inappetence, vomiting, lethargy, oral ulcers, dehydration. Uremic crisis possible.

When creatinine and SDMA stage differently — which occurs in roughly 17% of cats — IRIS recommends staging based on the higher of the two markers. SDMA is less influenced by muscle mass, making it particularly important in thin, sarcopenic senior cats whose creatinine may underestimate disease severity.

Stage at diagnosis is a strong predictor of survival. Survival data from a study of 2,211 cats with naturally occurring CKD (Boyd et al., 2008) showed median survival of approximately 1,151 days for Stage 2b cats (creatinine 203–249 μmol/L), 778 days for Stage 3 cats, and 103 days for Stage 4 cats. A separate analysis found that cats diagnosed at Stage 2 have a mean survival of approximately two to three years with appropriate management, while cats diagnosed at Stage 4 survive an average of less than six months. These are population averages — individual cats, particularly those that respond well to dietary intervention and phosphorus control, may live substantially longer.

Substaging: proteinuria and blood pressure

IRIS substaging addresses two risk factors that accelerate CKD progression independently of creatinine and SDMA. A Stage 2 cat with severe proteinuria and uncontrolled hypertension will progress faster than a Stage 3 cat with neither. That is why substaging drives treatment decisions at every stage.

Proteinuria (urine protein-to-creatinine ratio, UPC)

Substage	UPC ratio
Non-proteinuric	< 0.2
Borderline proteinuric	0.2–0.4
Proteinuric	> 0.4

A UPC above 0.4 in a cat with CKD is an independent risk factor for faster disease progression and shorter survival. Proteinuria reflects increased pressure and damage within the glomerulus. Reducing protein leakage — through RAAS blockade with telmisartan or benazepril — is a primary treatment target regardless of IRIS stage.

Blood pressure

Substage	Systolic blood pressure (mmHg)	Risk of target organ damage
Normotensive	< 150	Minimal
Borderline hypertensive	150–159	Low to moderate
Hypertensive	160–179	Moderate to high
Severely hypertensive	≥ 180	High

CKD is the most common cause of systemic hypertension in cats. Untreated hypertension causes target organ damage — retinal detachment and blindness, left ventricular hypertrophy, progressive nephron loss, and neurologic signs. IRIS recommends treating any cat with CKD and persistent systolic blood pressure above 160 mmHg.

Treatment by IRIS stage

Stage 1: establish baselines and address underlying causes

At Stage 1, creatinine and SDMA are not yet elevated beyond staging thresholds, but there is other evidence of kidney disease — a urine concentrating defect, abnormal kidney imaging, or persistently elevated SDMA between 14 and 18 μg/dL.

Treatment priorities at this stage:

• Complete baseline assessment: blood pressure, UPC ratio, urinalysis with urine culture, and imaging (renal ultrasound if not yet performed).
• Identify and address any reversible contributor: pyelonephritis, urinary obstruction, nephrolithiasis, or a primary disease causing secondary renal damage (hyperthyroidism, for example, can mask CKD by increasing renal perfusion — treating hyperthyroidism may unmask underlying CKD).
• Initiate monitoring schedule: recheck bloodwork and urine every 3–6 months. Track weight, body condition score (BCS), and muscle condition score (MCS) at every visit.
• Dietary discussion: there is no evidence that a renal diet is necessary at Stage 1, but discussing long-term nutrition strategy with the owner and establishing a baseline diet is reasonable. Cats are notoriously resistant to diet changes, and the earlier the owner begins a gradual transition, the more likely it is to succeed if and when a renal diet becomes indicated.

Stage 2: renal diet, phosphorus control, and the first treatment interventions

Stage 2 is where treatment begins to make a measurable difference in survival. The cornerstone is diet — specifically, a veterinary therapeutic renal diet with restricted phosphorus, modified protein, and enhanced potassium and B vitamins.

Renal diet evidence: The Elliott et al. randomized clinical trial remains the landmark study. Cats with spontaneous CKD (primarily Stage 2 and early Stage 3) fed a renal diet had a median survival of 633 days, compared to 264 days for cats maintained on a standard diet — a 2.4-fold difference. A second study reported median survival of 16 months on a renal diet versus 7 months on a maintenance diet. A 2026 study published in JAVMA found that cats consistently fed a renal diet across early CKD stages were 41–46% less likely to progress to a more advanced stage and had a 30% reduction in all-cause mortality.

Transition strategy matters: Cats are notoriously averse to diet changes, and compliance is a real clinical problem. Gradual transition over 2–4 weeks — mixing increasing proportions of the renal diet into the current food, warming the food to enhance aroma, and trying multiple brands/formulations if the first is rejected — improves the odds. Force-switching a cat who then stops eating is worse than staying on a maintenance diet, because anorexia triggers catabolism and muscle wasting, which worsens CKD.

Additional Stage 2 interventions:

• Phosphorus management: if serum phosphorus remains elevated despite renal diet, add a phosphate binder (discussed in detail below).
• Blood pressure control: if systolic blood pressure is persistently above 160 mmHg, start antihypertensive therapy. Amlodipine is the standard first-line agent.
• Proteinuria treatment: if UPC is above 0.4, start RAAS blockade with telmisartan or benazepril.

Stage 3: intensify all Stage 2 measures and add symptomatic support

At Stage 3, azotemia is moderate and clinical signs are usually apparent. Every intervention from Stage 2 continues — renal diet, phosphorus control, blood pressure management, proteinuria treatment — but symptomatic support becomes increasingly important.

Additional Stage 3 interventions:

• Phosphate binders: if renal diet alone has not brought serum phosphorus into the target range (mid-normal, ideally below 4.5 mg/dL), add a phosphate binder. Aluminum hydroxide, lanthanum carbonate, and sevelamer are the most commonly used options. These are mixed into food and bind dietary phosphate in the intestinal lumen, preventing absorption. Dose is titrated to effect — monitor serum phosphorus monthly until at target, then every 2–3 months.
• Appetite stimulants: inappetence drives weight loss and muscle wasting, which worsens CKD. Mirtazapine (a serotonin 5-HT3 receptor antagonist) and capromorelin (a ghrelin receptor agonist, marketed as Elura) are the two options. Both have evidence for increasing food intake in cats with CKD.
• Anti-nausea therapy: maropitant (Cerenia) is commonly used to manage nausea and vomiting in CKD cats. It is a neurokinin-1 (NK1) receptor antagonist that acts centrally in the vomiting center.
• Potassium supplementation: hypokalemia is common in CKD cats due to urinary potassium losses and reduced intake. If serum potassium is below the reference interval, oral potassium gluconate or potassium citrate supplementation is indicated. Hypokalemia worsens renal function and causes muscle weakness.
• More frequent monitoring: recheck every 2–3 months, or more frequently if the cat is clinically unstable.

Stage 4: palliative focus and quality of life

Stage 4 represents end-stage renal disease. The cat is markedly azotemic, usually clinically ill, and the goal of treatment shifts from slowing progression to maintaining comfort and quality of life.

Interventions at Stage 4:

• Subcutaneous fluid therapy: administered at home by the owner or at the clinic. Lactated Ringer's or 0.9% sodium chloride, typically 75–150 mL per session, 2–7 times per week depending on the cat's hydration status and tolerance. This addresses dehydration, helps flush uremic toxins, and can improve appetite and energy for a period. A study of owner experiences with at-home subcutaneous fluid therapy found that 85% of owners described the experience as easy or low-stress, and 89% reported a tolerable experience for their cats — making this a realistic home-care option for committed owners.
• Intensive symptom management: aggressive anti-nausea therapy, appetite stimulants, phosphate binders, and potassium supplementation as needed. The symptom burden is high, and multiple medications are often required simultaneously.
• Quality of life assessment: regular, honest conversations with the owner about the cat's quality of life. validated quality-of-life scales (such as the HHHHHMM Scale) can provide structure for these discussions. The goal is to prevent suffering while honoring the owner's wishes and the cat's dignity.
• End-of-life planning: when symptomatic treatment no longer maintains acceptable quality of life, humane euthanasia is the appropriate and compassionate recommendation. This conversation is difficult but should not be deferred until the cat is in crisis.

Diet: the single most impactful intervention

Of all the treatments available for feline CKD, renal diet has the strongest evidence for extending survival. The mechanism is primarily phosphorus restriction — phosphorus retention accelerates CKD progression through direct renal injury, secondary hyperparathyroidism, and mineral deposition in soft tissues.

The Elliott et al. trial demonstrated a median survival of 633 days on a renal diet versus 264 days on a maintenance diet. The 2026 JAVMA study reinforced this, showing 41–46% reduction in disease progression and 30% reduction in all-cause mortality with consistent renal diet use in early stages.

What a renal diet actually does differently from maintenance food:

• Phosphorus restriction: the most important component. Target dietary phosphorus is substantially lower than maintenance diets.
• Modified protein quantity and quality: not protein restriction per se — cats are obligate carnivores and protein restriction must be carefully balanced to avoid sarcopenia. The goal is to provide sufficient high-quality protein to maintain muscle while minimizing nitrogenous waste.
• Enhanced potassium and B vitamins: to replace urinary losses and address deficiencies common in CKD.
• Increased omega-3 fatty acids: for anti-inflammatory effects (the evidence for this specific component is weaker than for phosphorus restriction).
• Enhanced hydration profile: many renal diets are available in wet formulations to increase water intake.

For cats who absolutely will not eat a renal diet, a maintenance wet food with a phosphate binder mixed in is a pragmatic second choice — it is not as effective as a renal diet but is better than a maintenance dry food with no phosphorus restriction.

Proteinuria management: telmisartan vs. benazepril

Proteinuria (UPC > 0.4) in a CKD cat is treated with RAAS blockade. Two drug classes are available: ACE inhibitors (benazepril) and angiotensin II receptor blockers (telmisartan).

Benazepril

Benazepril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II. It has been used in feline CKD for decades. The evidence shows that benazepril consistently reduces proteinuria in CKD cats. However, the ACE inhibit trial in cats with CKD did not demonstrate a statistically significant survival benefit — treated cats survived a median of 501 days versus 391 days for placebo, but this difference did not reach statistical significance.

Telmisartan

Telmisartan (Semintra) is an angiotensin II receptor blocker (ARB). It has two advantages over ACE inhibitors:

1. Not susceptible to "ACE escape." Angiotensin II can be produced through non-ACE pathways (chymase, cathepsin G). ACE inhibitors do not block these alternative pathways; ARBs block angiotensin II at the receptor level regardless of the production pathway.
2. FDA-approved for feline hypertension. Semintra is labeled for the control of systemic hypertension in cats, giving it a regulatory advantage over benazepril (which is used off-label in cats in the US).

The key comparison trial is Sent et al. (2015), a prospective, multicenter, randomized, blinded study of 224 cats with CKD. Telmisartan (1 mg/kg) was non-inferior to benazepril for the primary endpoint (change in UPC). Notably, telmisartan significantly decreased UPC relative to baseline at all assessment points over 180 days, while benazepril did not show a statistically significant decrease at any assessment point.

Neither drug has demonstrated a statistically significant survival benefit

This is an honest caveat. Both drugs reduce proteinuria, and proteinuria is an independent risk factor for progression. But no trial has yet shown that reducing proteinuria with either drug translates into a statistically significant survival benefit in cats. The clinical rationale for treating proteinuria is strong, but the survival data remain indirect.

Monitoring when starting RAAS blockade

Both ACE inhibitors and ARBs can reduce glomerular filtration rate — the same mechanism that lowers intraglomerular pressure can also reduce overall kidney function, particularly in dehydrated cats. Check creatinine, SDMA, and electrolytes within 7–14 days of starting either drug or adjusting the dose. A rise in creatinine of more than 0.5 mg/dL or a greater than 25% increase in SDMA warrants dose reduction or discontinuation and reassessment of hydration status.

Hypertension management

Uncontrolled hypertension in CKD cats causes retinal detachment (sudden blindness), left ventricular hypertrophy, accelerated nephron loss, and neurologic signs including seizures and disorientation.

Amlodipine: the standard first-line agent

Amlodipine is a calcium channel blocker that has been the standard treatment for CKD-associated hypertension in cats for over two decades. It is effective, well tolerated, and inexpensive. Most cats respond to once-daily dosing. Blood pressure should be rechecked 7–14 days after starting or adjusting the dose.

Telmisartan: newly approved for feline hypertension

Semintra (telmisartan oral solution) is now FDA-approved for the control of systemic hypertension in cats. The approval data showed that Semintra reduced systolic blood pressure by approximately 19–23 mmHg by day 14, with over 50% of treated cats achieving systolic blood pressure below 150 mmHg by day 28.

For cats with both hypertension and proteinuria, telmisartan addresses both problems with a single agent — a meaningful simplification of the treatment protocol.

Blood pressure targets

IRIS recommends targeting systolic blood pressure below 150 mmHg to minimize risk of target organ damage. In cats with severe hypertension (above 200 mmHg), amlodipine remains the preferred initial agent until blood pressure is below this threshold, as telmisartan has not been evaluated as monotherapy in that population.

Phosphorus control beyond diet

When a renal diet alone does not bring serum phosphorus into the target range, phosphate binders are added. IRIS targets mid-normal serum phosphorus concentration, ideally below 4.5 mg/dL in CKD cats.

Common phosphate binders

Binder	Mechanism	Notes
Aluminum hydroxide	Binds phosphate in the GI tract	Inexpensive, widely available. Long-term use raises theoretical concern about aluminum accumulation, though clinical toxicity is uncommon in cats.
Lanthanum carbonate	Binds phosphate in the GI tract	Effective, minimal systemic absorption. More expensive.
Sevelamer	Binds phosphate in the GI tract	Non-absorbed, non-calcium, non-aluminum. Can be used in cats with hypercalcemia where calcium-based binders are undesirable.

All phosphate binders must be given with food to be effective — they work by binding dietary phosphate in the intestinal lumen. Giving a phosphate binder on an empty stomach provides no phosphorus-lowering benefit. Monitor serum phosphorus monthly until at target, then every 2–3 months.

FGF23: an emerging marker

Fibroblast growth factor 23 (FGF23) is a hormone produced by osteocytes in response to elevated phosphorus. In CKD, FGF23 rises early — before serum phosphorus becomes abnormal — as the body attempts to maintain phosphorus homeostasis. Elevated FGF23 has been associated with faster CKD progression in cats and is being investigated as a marker to guide the timing of phosphorus restriction. It is not yet part of standard clinical practice but may become part of the monitoring panel in the future.

Calcitriol: removed from IRIS recommendations

IRIS previously recommended calcitriol (active vitamin D) for managing secondary renal hyperparathyroidism in CKD cats. This recommendation has been removed due to insufficient evidence of clinical benefit. Some veterinarians still use calcitriol selectively, but it is no longer a guideline-endorsed intervention.

Monitoring schedule

Regular monitoring is how treatment decisions are made. The schedule below reflects IRIS-recommended intervals.

IRIS Stage	Recheck interval	What to check at each visit
1	Every 3–6 months	Weight, BCS, MCS, creatinine, SDMA, phosphorus, potassium, UPC, blood pressure, urinalysis
2	Every 3–4 months	Same panel as Stage 1. Add UPC and blood pressure if not previously assessed.
3	Every 2–3 months	Full panel. Add packed cell volume (PCV) to screen for anemia. Assess appetite, vomiting frequency, and hydration status.
4	Every 2–4 weeks or as needed	Full panel plus clinical assessment. Focus on symptom control, hydration, weight, and quality of life.

At every visit, regardless of stage: weigh the cat, assess body condition score and muscle condition score, and ask the owner about appetite, water intake, urine output, vomiting, and energy level. Trends matter more than any single value.

What treatment cannot do

CKD cannot be cured. The nephrons that have been lost do not regenerate. Treatment goals are to slow the rate of progression, manage complications (hypertension, proteinuria, hyperphosphatemia, hypokalemia, anemia, nausea), and maintain quality of life for as long as possible.

Kidney transplantation is available at a small number of veterinary specialty centers, but it is limited by cost, geographic availability, the need for lifelong immunosuppression, and donor availability. It is not a realistic option for most cats or most owners.

The practical aim of CKD management is to extend the period of good quality life — the months to years where the cat eats well, maintains weight, engages with the household, and has more good days than bad. That outcome is achievable in most cats diagnosed at Stage 2 or early Stage 3 with systematic staging, dietary compliance, and vigilant monitoring.

Sources

• IRIS — IRIS CKD Staging System. https://www.iris-kidney.com/iris-staging-system
• IRIS — IRIS CKD Treatment Guidelines. https://www.iris-kidney.com/iris-guidelines-1
• Elliott J, Rawlings JM, Markwell PJ, Barber PJ. Survival of cats with naturally occurring chronic renal failure: effect of dietary management. Journal of Small Animal Practice. 2000;41:235–242.
• Sent U, Gosl R, Elliott J, et al. Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease. Journal of Veterinary Internal Medicine. 2015;29:1479–1487. https://pubmed.ncbi.nlm.nih.gov/26474314/
• Coyne M, Szlosek D, Webeck J, et al. Use of a veterinary therapeutic renal diet in cats with early chronic kidney disease is associated with slower disease progression and improved survival. JAVMA. 2026;264(5):590–598. https://avmajournals.avma.org/view/journals/javma/264/5/javma.25.10.0665.xml
• PMC/NIH — Treatment options for hyperphosphatemia in feline CKD. https://pmc.ncbi.nlm.nih.gov/articles/PMC11383018
• Cornell Feline Health Center — Chronic Kidney Disease. https://www.vet.cornell.edu/departments-centers-and-institutes/cornell-feline-health-center/health-information/feline-health-topics/chronic-kidney-disease
• Merck Veterinary Manual — Chronic Kidney Disease in Small Animals. https://www.merckvetmanual.com/urinary-system/noninfectious-diseases-of-the-urinary-system-in-small-animals/chronic-kidney-disease-in-small-animals
• Veterinary Ireland Journal — Diagnosing and Staging Early Chronic Kidney Disease in Cats. https://www.veterinaryirelandjournal.com/small-animal/411-diagnosing-and-staging-early-chronic-kidney-disease-in-cats
• Today's Veterinary Practice — What's New in the Management of Feline Chronic Kidney Disease. https://todaysveterinarypractice.com/pharmacology/whats-new-in-the-management-of-feline-chronic-kidney-disease